엑셀릭시스 (EXEL) 주가

엑셀릭시스(EXEL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $58.36 (-0.22%), 시가총액 $12.49B, PER (주가수익비율) 16.46, 52주 최저~최고 $34.54 ~ $49.71.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an or

핵심 지표

• 현재가: $58.36 (-0.22%)
• 시가총액: $12.49B
• PER (주가수익비율): 16.46
• 52주 최저~최고: $34.54 ~ $49.71
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

엑셀릭시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

엑셀릭시스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 3.9

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 6.25
• 순이익률: 0.35%
• 영업이익률: 0.41%

자주 묻는 질문